Sanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...

Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) and Sanofi SA (NASDAQ:SNY) presented new, detailed results from the RELIEVE ...

Teva Pharmaceuticals and Alvotech have announced the US launch of Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...

EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

Selarsdi is approved by the FDA in several presentations, including 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled ...

Teva (TEVA) stock and Alvotech (ALVO) stock in focus as duo launches Selarsdi, a biosimilar to J&J's (JNJ) Stelara after a ...

Alvotech and Teva Pharmaceuticals said on Tuesday that the U.S. FDA has accepted for review a Biologics License Application ...

Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

Teva CEO Richard Francis said that he had not expected such a harsh reaction from the market but he sees a positive side to ...